Source link : https://www.newshealth.biz/health-news/fda-expands-dostarlimab-gxly-approval-for-endometrial-cancer/
The US Food and Drug Administration (FDA) has expanded the approval of dostarlimab-gxly (Jemperli, GSK) in conjunction with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adults with primary advanced or recurrent endometrial cancer. Prior FDA approval of the combination was granted for adults with primary advanced or recurrent endometrial cancer that was mismatch repair […]
Author : News Health
Publish date : 2024-08-02 11:53:43
Copyright for syndicated content belongs to the linked Source.
Categories